Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer

Novel anti-HER2 antibody-drug conjugates trastuzumab deruxtecan (DS-8201a) showed its effect in previously-treated HER2-low metastatic breast cancer, suggesting a promising future in HER2-low breast cancer. We retrospectively reviewed the clinicopathological data of 325 patients with stage I–III HER...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shuling, Liu, Ting, Kuang, Xiaying, Zhen, Tiantian, Shi, Huijuan, Lin, Ying, Shao, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792954/
https://www.ncbi.nlm.nih.gov/pubmed/36535072
http://dx.doi.org/10.1016/j.breast.2022.12.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792954/
https://www.ncbi.nlm.nih.gov/pubmed/36535072
http://dx.doi.org/10.1016/j.breast.2022.12.006

Ejemplares similares